MAO-B inhibitors
- Reduce dopamine breakdown in Parkinson disease
- Selegiline/rasagiline/safinamide
- Modest symptomatic benefit; reduce OFF time
- Selectivity is dose-dependent
- Low-dose MAO-B ≠ classic nonselective MAOI
- Interaction risk rises as MAO-A inhibition appears
- Safinamide also modulates glutamate release
Class at a glance
- Reduce dopamine breakdown in Parkinson disease
Members / distinctions
- Selegiline/rasagiline/safinamide
- Modest symptomatic benefit; reduce OFF time
Other member distinctions
- Selectivity is dose-dependent
- Low-dose MAO-B ≠ classic nonselective MAOI
- Safinamide also modulates glutamate release
Safety / monitoring
- Interaction risk rises as MAO-A inhibition appears
Self-check
- What do MAO-B inhibitors primarily reduce?
dopamine breakdown in Parkinson disease.
Drugs in this class (3)
All drug classes · Open the interactive console ↗
